European Journal of Clinical Pharmacy

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

Topical finasteride in Europe is often seen as less effective than oral forms, with users suggesting alternative application methods for better results. Many prefer oral finasteride due to cost and effectiveness.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil (fluridil) is approved as a cosmetic hair-care agent in Europe, but users question the level of testing required for approval.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

Sugary beverages increase the risk of pattern hair loss in men by 57%. Treatments discussed include Minoxidil, finasteride, and RU58841.